title: Treatment of acromegaly with long acting somatostatin analogue SMS 201-995.
abstract: Ten acromegalic patients were treated with the somatostatin analogue SMS 201-995 (SMS) for 3-38 weeks in various doses and by different administration routines (thrice daily or multiple sc injection). Plasma GH daily profiles, plasma IGF-I, urinary GH, serum TSH, IRI and fasting blood glucose (FBG) concentrations were measured before and during SMS treatment. Plasma GH rapidly decreased within one hour in all patients and was suppressed for at least 4 h after a 50 micrograms sc injection of SMS in 8 patients. Multiple injections of 300-600 micrograms/day SMS (25-50 micrograms X 12) suppressed GH throughout the day. Plasma IGF-I was completely normalized in 4 patients, and, in all but one of the others, decreased markedly. Urinary GH decreased within the first week of treatment in all patients and normalization was obtained in 3 patients. Shrinkage of the pituitary tumor, as determined by CT or MRI, was observed in 7 of 9 patients. Other clinical improvements, such as diminution or complete disappearance of swelling of soft tissues, excessive perspiration, and headache, were observed in 7 of 8 patients. Changes in serum TSH, IRI and FBG were seen in 3-4 patients, but without any apparent clinical problems. In conclusion, SMS is a useful clinical tool for treatment of acromegaly, and a multiple sc injection method seems to be preferable.
authors.affiliation: Department of Medicine, Tokyo Women's Medical College, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Horikawa
authors.forename: K
authors.initials: K
authors.lastname: Takano
authors.forename: N
authors.initials: N
authors.lastname: Hizuka
authors.forename: K
authors.initials: K
authors.lastname: Asakawa
authors.forename: I
authors.initials: I
authors.lastname: Sukegawa
authors.forename: N
authors.initials: N
authors.lastname: Hirose
authors.forename: N
authors.initials: N
authors.lastname: Horiba
authors.forename: K
authors.initials: K
authors.lastname: Kasono
authors.forename: A
authors.initials: A
authors.lastname: Masuda
authors.forename: Y
authors.initials: Y
authors.lastname: Ohba
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D015282:Octreotide